文献速递心脑血管急症消化、代谢与肾脏急症

氯噻酮与氢氯噻嗪用于心肌梗死或卒中后高血压治疗:一项随机临床试验的二次分析

Chlorthalidone vs Hydrochlorothiazide for Hypertension Treatment After Myocardial Infarction or Stroke: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2024-05-01
一句话结论DCP二次分析提示,既往心肌梗死或卒中患者用氯噻酮较氢氯噻嗪主要不良心血管事件和非癌死亡风险更低(HR 0.73)。

该研究为Diuretic Comparison Project(DCP)的预设二次分析,纳入72个退伍军人事务医疗系统、年龄65岁及以上、基线服用氢氯噻嗪的高血压患者,随机继续氢氯噻嗪或换用氯噻酮。在基线有心肌梗死或卒中者(n=1455)中,氯噻酮组主要终点发生率14.3% vs 氢氯噻嗪组19.4%(HR 0.73;95%CI 0.57-0.94;P=.01);无心肌梗死或卒中者(n=12068)中为9.9% vs 8.9%(HR 1.12;95%CI 1.00-1.26;P=.054),交互作用P=.01。作者认为,在既往心肌梗死或卒中患者中,氯噻酮可能与主要不良心血管事件和非癌死亡减少相关。

要点

  • 既往心肌梗死或卒中患者:氯噻酮组主要终点14.3%(105/733) vs 氢氯噻嗪组19.4%(140/722),HR 0.73(95%CI 0.57-0.94;P=.01)。
  • 无心肌梗死或卒中患者:氯噻酮组主要终点9.9%(597/6023) vs 氢氯噻嗪组8.9%(535/6045),HR 1.12(95%CI 1.00-1.26;P=.054)。
  • 治疗分组与心肌梗死或卒中史的交互作用P=.01。
  • 无心肌梗死或卒中者低钾血症(血钾<3.1 mEq/L)氯噻酮组4.9%(292/6023) vs 氢氯噻嗪组3.4%(206/6045),P<.001;低钾血症住院1.4%(84/6023) vs 0.9%(57/6045),P=.02。
  • 既往心肌梗死或卒中者低钾血症(血钾<3.1 mEq/L)5.9%(43/733) vs 5.1%(37/722),P=.57;低钾血症住院1.9%(14/733) vs 2.2%(16/722),P=.72。

适用人群与场景

  • 年龄65岁及以上、基线服用氢氯噻嗪的高血压患者,来自72个退伍军人事务医疗系统。
  • 按基线有无心肌梗死或卒中史分为两个亚组:有既往心肌梗死或卒中(n=1455)和无既往心肌梗死或卒中(n=12068)。

诊断标准与关键阈值

  • 低钾血症定义为血钾水平<3.1 mEq/L(换算为mmol/L需乘以1.0)。

处置流程与药物剂量

  • 随机继续氢氯噻嗪或换用氯噻酮,两组使用药理学可比日剂量。

研究设计与关键结果

  • 研究类型:Diuretic Comparison Project(DCP)的预设二次分析,该试验为实用性随机临床试验,在72个退伍军人事务医疗系统开展,2016年6月至2021年6月;本二次分析于2023年1月3日至2024年2月29日进行。
  • 样本量与人群:DCP随机13523例至氯噻酮或氢氯噻嗪,平均(SD)研究时长2.4(1.4)年;基线中位年龄72岁(IQR 69-75岁),96.8%为男性。
  • 主要终点:卒中、心肌梗死、因不稳定型心绞痛紧急冠状动脉血运重建、急性心力衰竭住院或非癌死亡的复合终点。
  • 有既往心肌梗死或卒中者:氯噻酮组主要终点105/733(14.3%) vs 氢氯噻嗪组140/722(19.4%),HR 0.73(95%CI 0.57-0.94;P=.01)。
  • 无既往心肌梗死或卒中者:氯噻酮组主要终点597/6023(9.9%) vs 氢氯噻嗪组535/6045(8.9%),HR 1.12(95%CI 1.00-1.26;P=.054)。
  • 治疗分组与心肌梗死或卒中史的交互作用P=.01。
  • 低钾血症(血钾<3.1 mEq/L):有既往心肌梗死或卒中者氯噻酮组43/733(5.9%) vs 氢氯噻嗪组37/722(5.1%),P=.57;无既往心肌梗死或卒中者氯噻酮组292/6023(4.9%) vs 氢氯噻嗪组206/6045(3.4%),P<.001。
  • 低钾血症住院:有既往心肌梗死或卒中者氯噻酮组14/733(1.9%) vs 氢氯噻嗪组16/722(2.2%),P=.72;无既往心肌梗死或卒中者氯噻酮组84/6023(1.4%) vs 氢氯噻嗪组57/6045(0.9%),P=.02。

证据类型、等级与局限

  • 证据类型:实用性随机临床试验的预设二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在既往心肌梗死或卒中患者中,氯噻酮与氢氯噻嗪相比可能与主要不良心血管事件和非癌死亡减少相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Patients with prior myocardial infarction (MI) or stroke have a greater risk of recurrent cardiovascular (CV) events.

OBJECTIVE: To evaluate the association of chlorthalidone (CTD) vs hydrochlorothiazide (HCTZ) with CV outcomes and noncancer deaths in participants with and without prior MI or stroke.

DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified secondary analysis of the Diuretic Comparison Project (DCP), a pragmatic randomized clinical trial conducted within 72 participating Veterans Affairs health care systems from June 2016 to June 2021, in which patients aged 65 years or older with hypertension taking HCTZ at baseline were randomized to continue HCTZ or switch to CTD at pharmacologically comparable doses. This secondary analysis was performed from January 3, 2023, to February 29, 2024.

EXPOSURES: Pharmacologically comparable daily dose of HCTZ or CTD and history of MI or stroke.

MAIN OUTCOMES AND MEASURES: Outcome ascertainment was performed from randomization to the end of the study. The primary outcome consisted of a composite of stroke, MI, urgent coronary revascularization because of unstable angina, acute heart failure hospitalization, or noncancer death. Additional outcomes included achieved blood pressure and hypokalemia (potassium level <3.1 mEq/L; to convert to mmol/L, multiply by 1.0).

RESULTS: The DCP randomized 13 523 participants to CTD or HCTZ, with a mean (SD) study duration of 2.4 (1.4) years. At baseline, median age was 72 years (IQR, 69-75 years), and 96.8% were male. Treatment effect was evaluated in subgroups of participants with (n = 1455) and without (n = 12 068) prior MI or stroke at baseline. There was a significant adjusted interaction between treatment group and history of MI or stroke. Participants with prior MI or stroke randomized to CTD had a lower risk of the primary outcome than those receiving HCTZ (105 of 733 [14.3%] vs 140 of 722 [19.4%]; hazard ratio [HR], 0.73; 95% CI, 0.57-0.94; P = .01) compared with participants without prior MI or stroke, among whom incidence of the primary outcome was slightly higher in the CTD arm compared with the HCTZ arm (597 of 6023 [9.9%] vs 535 of 6045 [8.9%]; HR, 1.12; 95% CI, 1.00-1.26; P = .054) (P = .01 for interaction). The incidence of a nadir potassium level less than 3.1 mEq/L and hospitalization for hypokalemia differed among those with and without prior MI or stroke when comparing those randomized to CTD vs HCTZ, with a difference only among those without prior MI or stroke (potassium level <3.1 mEq/L: prior MI or stroke, 43 of 733 [5.9%] vs 37 of 722 [5.1%] [P = .57]; no prior MI or stroke, 292 of 6023 [4.9%] vs 206 of 6045 [3.4%] [P < .001]; hospitalization for hypokalemia: prior MI or stroke, 14 of 733 [1.9%] vs 16 of 722 [2.2%] [P = .72]; no prior MI or stroke: 84 of 6023 [1.4%] vs 57 of 6045 [0.9%] [P = .02]).

CONCLUSIONS AND RELEVANCE: Results of this secondary analysis of the DCP trial suggest that CTD may be associated with reduced major adverse CV events and noncancer deaths in patients with prior MI or stroke compared with HCTZ.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02185417.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Ishani A, Hau C, Cushman WC, et al. Chlorthalidone vs Hydrochlorothiazide for Hypertension Treatment After Myocardial Infarction or Stroke: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 38743423. doi:10.1001/jamanetworkopen.2024.11081

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。